Bayer says legal woes could force it to pull weedkiller

Bayer says legal woes could force it to pull weedkiller

Bayer has been dogged by lawsuits linked to the weedkiller Roundup since it acquired the US manufacturer Monsanto in a blockbuster deal in 2018
Bayer has been dogged by lawsuits linked to the weedkiller Roundup since it acquired the US manufacturer Monsanto in a blockbuster deal in 2018. Photo: Robyn Beck / AFP/File
Source: AFP

German chemicals giant Bayer said Friday it could be forced to pull its Roundup weedkiller from the market if it is not able to limit simmering legal troubles.

"We're nearing a point where the litigation industry could force us to even stop selling this vital product," CEO Bill Anderson said at Bayer's annual general meeting.

The Leverkusen-based group has said that after rumbling on for years, it has the aim of "significantly containing litigation by the end of 2026".

"The status quo is not an option," said Anderson, while the stakes for the chemicals and pharmaceuticals producer were "really high".

Bayer has been dogged by lawsuits linked to Roundup since it acquired the US manufacturer Monsanto in a blockbuster deal in 2018.

Claimants have alleged that glyphosate, the active ingredient in Roundup, causes blood cancers but Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.

Read also

Intel chief vows to thin ranks at US chip maker

Bayer has battled to draw a line under Roundup litigation, spending more than $10 billion (8.8 billion euros) to date to settle suits alleging that Bayer failed to disclose health risks.

Earlier this month, Bayer said it would launch another appeal to the US Supreme Court to rule on the Roundup case, its third such attempt.

After being twice rebuffed by the court, Bayer is hopeful of more success following rulings by federal appellate courts, which the German group said support its case.

The renewed request for the Supreme Court to intervene is the first since Anderson took the reins at the chemicals group in 2023.

But Anderson's late arrival has not insulated the American manager from the criticism of shareholders, who voiced their impatience at the meeting.

Bayer has asked investors to approve a capital increase through the issuance of new stock to cover potential legal costs related to Roundup.

Read also

Alphabet quarterly earnings lifted by cloud and AI

Shareholders were being asked to "pay the price" for Roundup's issues, Deka Investment manager Ingo Speich said, describing the move as a "bitter pill to swallow".

"Why should everything be different this time and the wave of lawsuits stopped with more money?", Janne Werning of Union Investment said.

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.